Arkolith/Insider Trading/XENE/Form 4

Gannon Steven

DirectorXenon Pharmaceuticals Inc. (XENE) · full profile →Form 4 · filed Jun 6, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$91
Net Open-Market Flow
-$91
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 5, 2025Sell(S)3$30.48$917K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 5, 2025Grant(A)17K—$017K
Jun 5, 2025Grant(A)3K—$03K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-083321) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML